BioProtect develops radiation protection technology in the healthcare industry. The company offers biodegradable balloon spacers that create a safe distance between the prostate and rectum during radiation therapy, reducing radiation exposure to healthy tissue. It serves the oncology sector, with a particular emphasis on prostate cancer treatment. The company was founded in 2004 and is based in Tzur Yigal, Israel.
BioProtect has filed 9 patents.
Radiation therapy, Medical physics, Cell cycle, Biotechnology, Polymers
Radiation therapy, Medical physics, Cell cycle, Biotechnology, Polymers
Latest BioProtect News
Sep 28, 2023
The medical device company will use the financing to support the US commercialisation of its BioProtect Balloon Implant System, designed to provide optimal, consistent, and reproducible protection to the rectum during prostate cancer radiation therapy BioProtect Balloon Implant System. (Credit: PRNewswire/BioProtect) BioProtect, an Israeli medical technology company focused on biodegradable spacing solutions, has closed a $28m funding round led by MVM Partners, which invests in healthcare companies. The existing investors including Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz also participated in the funding round. As part of the financing, MVM partner Kevin Cheng will be appointed to BioProtect’s board of directors, along with Stephen Reeders. MVM partner Kevin Cheng said: “MVM aims to make best-in-class healthcare innovations more widely available to patients. We are impressed by the compelling benefits of BioProtect’s next-generation spacer and are thrilled to support the US commercial launch of this technology.” The medical device company intends to use the proceeds from the financing to support the commercialisation of its BioProtect Balloon Implant System in the US. The BioProtect Balloon Implant System is a new-generation spacer designed to provide optimal, consistent, and reproducible protection to the rectum during prostate cancer radiation therapy. It is said to provide reproducible separation between the prostate and rectum, which is visible in all imaging modalities like MRI, CT, and ultrasound. The balloon implant system has recently been approved by the US Food and Drug Administration (FDA), for rectal protection during radiation therapy for prostate cancer. BioProtect CEO Itay Barnea said: “We believe that our balloon has the potential to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy. “To date, our spacer has been successfully implanted in over 2,000 patients worldwide and has proven to be safe and effective. “We appreciate the support of our new and existing investors who share our vision for the company and are pleased to secure the resources to drive our penetration into the US market.” Do you have interesting content to share with us? Enter your email address so we can get in touch. Related Article
BioProtect Frequently Asked Questions (FAQ)
When was BioProtect founded?
BioProtect was founded in 2004.
Where is BioProtect's headquarters?
BioProtect's headquarters is located at 8 Tsor Street, Tzur Yigal.
What is BioProtect's latest funding round?
BioProtect's latest funding round is Series E.
How much did BioProtect raise?
BioProtect raised a total of $64.25M.
Who are the investors of BioProtect?
Investors of BioProtect include Peregrine Ventures, KB Investment, MVM Partners, Consensus Business Group, Almeda Ventures and 9 more.
Who are BioProtect's competitors?
Competitors of BioProtect include Gynesonics, GENICON, Dune Medical Devices, NinePoint Medical, Magnetecs and 7 more.
Compare BioProtect to Competitors
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
MST - Medical Smart Tools was founded in 2004 with the mission to develop image guided surgery technology solutions. The Company aims to improve laparoscopic and other minimally invasive surgical procedures and medical staff effectiveness, thus increasing hospital efficiencies, reducing surgical costs, and improving patient outcomes. MST is working within NGT, a private technological incubator in Nazareth, Israel. MST presents the market with a smart disposable Robotic Arm camera holder for laparoscopy, based on advanced image technology. The system is comprised of a computer-controlled mechanism for mechanical camera motivation, intuitive interface between the surgeon and the mechanical system. The company's R&D efforts are spearheaded by a core group of engineers with expertise in image processing, dynamics of mechanisms, multi-link systems and biomechanics. The Company is backed by strong and experienced management and professional medical advisors.
SuturTek is a healthcare company with a patented platform technology for a portfolio of products that aim to precisely replicate traditional hand suturing techniques providing faster, easier, safer suturing in both currently sutured procedures as well as additional open and minimally invasive procedures. It's first product was for fascia closure and was followed by a sternum closing device.
Magnetecs is a company that focuses on the design and manufacture of medical technology, specifically within the healthcare industry. The company's main product is a robotic Catheter Guidance Control and Imaging (CGCI) system, which is used for minimally invasive medical procedures. This system uses an electromagnetic array to guide a magnetically-tipped catheter, allowing physicians to control surgical tools with precision and consistency, enhancing safety and dexterity. It is based in Inglewood, California.
Sierra Surgical Technologies is a developer of minimally invasive surgical systems.
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.